🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to be at #ASCO2025 with an oral presentation of updated TRAVERSE data on ALLO-316 in #RCC and a trial-in-progress poster on the ALPHA3 trial investigating cema-cel in 1L #LBCL. #CART #CellTherapy $ALLO

We are looking forward to our fireside chat at the upcoming Jefferies Global Healthcare Conference. Tune in to hear why we believe in the future of AlloCAR T™ products. Webcasts available in the IR section of our website. #CART $ALLO Tune Into Our Fireside Chat:

What if you could predict and prevent relapse in #DLBCL? Don’t miss this Satellite Symposium at #ICML2025, where experts will discuss potentially advancing beyond "watch and wait" with investigational MRD testing and allogeneic #CART. #Immunotherapy $ALLO Register Here:

Excited to present updated findings from the TRAVERSE trial evaluating ALLO-316 in #RCC at #ASCO25, learn more here: ir.allogene.com/news-releases/…

Thank you Dr. Srour for sharing exciting new data from the TRAVERSE trial evaluating ALLO-316 in #RCC. Learn more here: ir.allogene.com/news-releases/…

Thank you Dr. Jason Westin, Jason Westin, MD FACP FASCO, for your poster presentation on the ALPHA3 trial and the potential of investigational cema-cel to change how early-stage #LBCL is treated. allogene.com/alpha3/

Learn more about our exciting new data from the TRAVERSE trial of ALLO-316 in patients with #RCC presented at #ASCO25. ir.allogene.com/news-releases/…

Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are aiming to leverage the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. $ALLO #CART

Join us at our Satellite Symposium at #ICML2025, where leading experts will explore how pairing advanced investigational MRD testing with allogeneic #CART could reshape the treatment landscape for #DLBCL. Don’t miss this look at the future of care. #Immunotherapy $ALLO Register

Investigational AlloCAR T™ products are designed to overcome limitations of today’s autologous therapies and deliver these transformative treatments to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access:

Join us at #ICML2025 for a Satellite Symposium, where leading experts will discuss the potential benefits of combining investigational MRD testing with allogeneic #CAR T in #DLBCL patients. $ALLO Register Here: forms.office.com/Pages/DesignPa…

We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s

Thank you to everyone who joined our Satellite Symposium at #ICML2025. It was an honor to convene experts to explore the promise of MRD testing and allogeneic #CART. We’re grateful to all who made it possible and excited to advance this vision through our ongoing ALPHA3 study.

At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #Immunotherapy Explore Innovation at Allogene:

Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy

Insights from our CEO David Chang on why today's acquisition of Capstan Therapeutics by AbbVie signals a bright future ahead for cell therapy and future innovation. bit.ly/4nrkY9V

Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are aiming to leverage the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. $ALLO #CART

We at Allogene Therapeutics are proud to help carry Dr. Zelig Eshhar's vision forward and continue building on the scientific breakthroughs he helped ignite. Thank you arie_belldegrun for sharing your memories. #ZeligEshhar #CART #immunotherapy #Legacy

Investigational AlloCAR T™ products are designed to overcome limitations of today’s autologous therapies and deliver these transformative treatments to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access: